
|Videos|February 1, 2022
Investigators analyze patterns of treatment preferences in patients with OAB
Author(s)Urology Times staff
“Our goal was to educate these patients thoroughly on the risks and benefits of each of these therapies, and try to understand what guides their choice of third line therapy based on their lifestyle and what suits them,” says Anjali Kapur, MD.
Advertisement
In this video, Anjali Kapur, MD, and Jason Kim, MD, discuss the background and findings of the study, “Patient preference of third line therapy for overactive bladder,” which will be presented at the Society of Women in Urology Annual Clinical Mentoring Conference. Kapur is a PGY-4 resident and Kim is an associate professor of urology, director of the Women’s Pelvic Health and Continence Center, and urology residency program director at Stony Brook Medicine in East Setauket, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












